NEOVACS SA Share Price Deutsche Boerse AG

0LW

FR001400HDX0

Biotechnology & Medical Research

End-of-day quote Deutsche Boerse AG Other stock markets 07:06:03 15/11/2023 GMT			5-day change	1st Jan Change
0.000500 ^EUR	-.--%		-.--%	-

02-10	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
11-20	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI

News in other languages: NEOVACS SA

07:01am	Neovacs : Cotation des actions Néovacs regroupées
06-15	Financements dilutifs et fonds vautours : le législateur s'en mêle enfin
05-22	Bourse : Richemont brille, Estée Lauder renonce à Puig, Kioxia grossit
05-22	L'IA reprend le leadership
05-04	Bourse : GameStop veut racheter Ebay, game over pour Spirit, Engie accélère dans l'éolien

More news

Managers and Directors: NEOVACS SA

Manager	Title	Age	Since
Hugo Brugière CEO	Chief Executive Officer	-	-
Alexandre Courtoux DFI	Director of Finance/CFO	-	30/09/2020
Laurent Reber CTO	Chief Tech/Sci/R&D Officer	56	-

Director	Title	Age	Since
Jean-Jacques Bertrand CHM	Chairman	87	27/05/2003
Baudouin Hallo BRD	Director/Board Member	-	30/04/2020
Hugo Brugière CHM	Chairman	-	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEOVACS SA	-.--%	-.--%	-	-	276K
LONZA GROUP AG	+0.94%	+8.20%	-4.77%	+1.97%	46.2B
REVOLUTION MEDICINES, INC.	+5.45%	+15.83%	+422.02%	+632.46%	38.71B
IQVIA HOLDINGS INC.	-1.37%	+15.19%	+22.66%	-12.70%	31.9B
BEONE MEDICINES AG	+3.97%	+6.12%	+19.15%	+61.50%	31.12B
CELLTRION, INC.	+8.02%	+5.23%	+17.67%	+35.36%	23.77B
ASCENDIS PHARMA A/S	+36.91%	+15.29%	-	-	16.2B
MEDPACE HOLDINGS, INC.	-0.03%	+17.20%	+70.16%	+127.31%	15.05B
EUROFINS SCIENTIFIC SE	-1.13%	+9.05%	+12.03%	+18.95%	13.74B
IONIS PHARMACEUTICALS, INC.	+2.49%	+6.48%	+104.53%	+96.57%	13.42B
Average	+2.16%	+10.60%	+82.93%	+120.18%	25.57B
Weighted average by Cap.	+2.56%	+10.07%	+95.73%	+142.09%

See all sector performances

NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

As early as today, start finding the best investment opportunities!

Market Cap	4.09K 4.67K 3.77K 3.53K 6.64K 442K 6.79K 45.43K 17.54K 218K 17.54K 17.15K 756K	P/E 2023 *	-	P/E 2024	-
Enterprise Value	-201K -230K -186K -173K -326K -21.7M -334K -2.23M -862K -10.71M -862K -843K -37.17M	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	0.01%	Yield 2023 *	-	Yield 2024	-

02-10	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
11-20	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
20/10/25	Neovacs S.A. announced that it expects to receive ?0.25 million in funding	CI
11/08/25	Neovacs S.A. announced that it has received ?0.25 million in funding from European High Growth Opportunities Manco S.A.	CI
29/04/25	Neovacs S.A. Auditor Raises 'Going Concern' Doubt	CI
29/04/25	Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
16/03/25	Neovacs S.A. announced a financing transaction	CI
04/02/25	Neovacs: consideration of delisting, share price surges
04/11/24	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
01/11/24	Tech's Tangled Path with Microsoft
17/06/24	Neovacs: collaboration agreement with CNRS
10/06/24	Neovacs: presents results from vaccine candidates
04/06/24	Néovavs: raises 200,000 euros through the issue of OCEANE-BSA bonds

	2023	2024
Net sales	533K 609K 492K 460K 866K 57.6M 885K 5.93M 2.29M 28.41M 2.29M 2.24M 98.65M	434K 496K 401K 374K 704K 46.85M 720K 4.82M 1.86M 23.12M 1.86M 1.82M 80.25M
Net income	-8.74M -9.99M -8.07M -7.54M -14.19M -944M -14.51M -97.13M -37.5M -466M -37.5M -36.68M -1.62B	-32.91M -37.59M -30.39M -28.37M -53.41M -3.55B -54.63M -366M -141M -1.75B -141M -138M -6.09B
Net Debt	-237K -270K -218K -204K -384K -25.54M -393K -2.63M -1.01M -12.6M -1.01M -992K -43.74M	-205K -234K -189K -177K -333K -22.14M -340K -2.28M -880K -10.92M -880K -860K -37.93M

NEOVACS SA Share Price Deutsche Boerse AG

Stocks

0LW

FR001400HDX0

Biotechnology & Medical Research

Valuation: NEOVACS SA

Latest news : NEOVACS SA

News in other languages: NEOVACS SA

Quotes and Performance

Course Extremes

Managers and Directors: NEOVACS SA

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

1 week	0		5
1 month	0		10